Navigation Links
Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
Date:12/27/2007

Investor Conference Call Scheduled for December 28, 2007 at 8:30 a.m

Eastern Time

PALO ALTO, Calif., Dec. 27 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it has initiated a license and development partnership with Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) for AZ-003 (Staccato(R) fentanyl) and the fentanyl class of molecules for North America. Currently in Phase 1 clinical development, AZ-003 is a hand-held drug device that uses Alexza's proprietary Staccato system inhalation technology to deliver fentanyl for the treatment of breakthrough pain in cancer and non-cancer patients.

"We have consistently reiterated how important it is for Alexza to develop the possible tamper and diversion-resistant attributes of our AZ-003 product with an established market leader in pain management," said Thomas B King, President and CEO of Alexza. "We believe Endo is an ideal partner for AZ-003. We look forward to working together with them to develop this important new technology and product for the opioid markets."

Under the terms of the agreement, Endo will pay Alexza an upfront fee of $10 million, with additional payments of up to $40 million upon achievement of predetermined regulatory and clinical milestones. Endo will also pay undisclosed royalties to Alexza on net sales of the product, from which Alexza will pay for the cost of goods for the manufacture of commercial product. In the partnership, Alexza has primary respons
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Report Details ... highest potential revenues Do you want to find ... you revenue predictions for those biological drugs from ... you find financial data, R&D trends, opportunities and ... sales forecasts to 2024 at overall world market, ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market is ... increased acceptance of new filtration technologies in end users ... also catalyzing the growth of laboratory filtration market. , ... at a strong CAGR during the forecast period of ... by 2019. The market is mainly driven by the ...
(Date:9/30/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" ... a Canadian Patent for Inhibition or Reversal of ... claims using thymosin beta 4, various fragments and ... purposes.  The patent will expire in 2021. ... ) RegeneRx is focused on ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... announced that Ricky Takai, Ph.D., has joined the company ... the firm, Dr. Takai will become the leader of ... Takai brings his more than 20 years experience in ... the field of education to the company.Most recently, Dr. ...
... Inc. (Nasdaq: BMRN ) today announced ... placebo-controlled clinical study of 6R-BH4 in patients with ... no statistical significance observed between the 6R-BH4 treatment ... peak walking time (PWT), did not show a ...
... CHICAGO, Feb. 3 Advanced Life Sciences Holdings,Inc. (Nasdaq: ... the discovery,development and commercialization of novel drugs in the ... that the Company,will make a corporate presentation to investors ... Company,s presentation will be delivered in the Windsor Suite,at ...
Cached Biology Technology:Dr. Ricky Takai, Expert in Designing and Managing Federal Evaluation Studies in Education, Joins Abt Associates 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 2Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 3
(Date:10/1/2014)... October 1, 2014 Novel ... life science field  The life science ... go over the years. Some are shooting stars ... is a novel detection technology that has raised ... finally, this technology is becoming commercially available. With ...
(Date:9/30/2014)... something that we enjoy when we visit a national park ... of ourselves as a part of nature? A bird,s nest ... , The answers to these questions reflect different cultural ... and in cultural artifacts. , A new Northwestern University study, ... Center of Chicago and the Menominee tribe of Wisconsin, focuses ...
(Date:9/30/2014)... and Howard Hughes Medical Institute investigator, and Margarita ... in the 2014 round of grants from the ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative for ... 30, provides more than $3 million in funding ... The BRAIN Initiative, launched last year, is a ...
Breaking Biology News(10 mins):First-of-a-kind Solution for Utilizing Photon Upconversion 2The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2
... than a dozen countries joined together to sequence the tomato ... The Tomato Genomics Consortium directed the research effort, which ... Foundation and the USDA,s Agriculture Research Services. The OU ... Emeritus in the College of Arts and Sciences, was one ...
... 2012) -- A detailed analysis of more than 4 ... help electricity producers slash as much as 30 percent ... dioxide from power plant emissions. The research by ... Lawrence Berkeley National Laboratory (LBNL) and the Electric Power ...
... Madrid, May, 31st, 2012.- Madrid will become ... during the Biomedical Innovation Conference 2012, focused on ... Madrid-MIT M+Vision Consortium. This new organization has been ... and the regional Government of the Comunidad de ...
Cached Biology News:New materials could slash energy costs for CO2 capture 2New materials could slash energy costs for CO2 capture 3MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012 2
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
... Collagen I 60 mm Culture Dishes BD ... treated polystyrene with a uniform application of rat ... Collagen I ,Surface : ECM/attachment ... ,Dim nominal : 60 mm x ...
...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
Biology Products: